FDA grants accelerated approval to Trodelvy for the treatment of metastatic urothelial cancer- Gilead Sciences
Johnson & Johnson statement on COVID 19 vaccine -JNJ 78436735.(Updated)
First patient dosed in phase III XTEND-Kids study with efanesoctocog alfa in children with haemophilia A.- Swedish Orphan Biovitrum.
Myovant Sciences and Pfizer announce first participant dosed in phase III SERENE study of relugolix combination tablet for contraception.
Positive topline data shows fostamatinib meets primary endpoint of safety in phase II patients with COVID-19.- Rigel Pharma
Endo announces publication of phase III Qwo (collagenase clostridium histolyticum-aaes) data in peer-reviewed Dermatologic Surgery journal.
FDA accepts sNDA for Xywav to treat with idiopathic hypersomnia with PDUFA date on 12 August 2021- Jazz Pharma
Arcutis initiates phase III clinical trial of topical roflumilast cream (ARQ 151) as a potential treatment for atopic dermatitis in pediatric patients between the ages of two and five years.
Update on the DARE-19 phase III trial for Farxiga in COVID-19.- AstraZeneca
FDA approves Xolair prefilled syringe for self-injection across all indications Genentech + Novartis
Phase III REGN-COV 2069 trial of REGN-COV2 meets endpoints in COVID-19.- Roche
Adamis Pharmaceuticals provides an update on ZIMHI, high-dose naloxone injection product intended for the treatment of opioid overdose.
BeiGene presents interim analysis results of RATIONALE 303 trial of tislelizumab in second- or third-line non-small cell lung cancer at the AACR Annual Meeting .
Phase III CHRONOS-3 trial of Aliqopa and Rituxan in non-Hodgkin’s Lymphoma published in The Lancet Oncology.- Bayer HealthCare
Hypothesis for rare side effect linked to AstraZeneca vaccine.
Pfizer announces extension of review of NDA for abrocitinib for treatment of atopic dermatitis and for Xeljanz for ankylosing spondylitis.
Provention Bio provides regulatory update on BLA for teplizumab for delay or prevention of type 1 diabetes in at-risk individuals.
New real-world observational analysis of Uptravi underscores the importance of risk assessment for treating pulmonary arterial hypertension patients.-Johnson & Johnson
Phase III CheckMate -816 study of Opdivo + chemo shows positive response in NSCLC.- BMS
Positive results from the sutimlimab pivotal trial for people with cold agglutinin disease published in New England Journal of Medicine.- Sanofi
Scilex Holding /Sorrento Therapeutics has received a sNDA approval from the FDA for ZTlido to make efficacy labeling change with clinical data for post-herpetic neuralgia.
Seagen + Genmab announce FDA filing acceptance for priority review of tisotumab vedotin BLA for patients with recurrent or metastatic cervical cancer.
Lilly and Incyte announce results from the phase III COV-BARRIER study of baricitinib in hospitalized COVID-19 patients.
FDA approves Trodelvy, the first treatment for metastatic triple-negative breast cancer shown to improve progression-free survival and overall survival.- Gilead Sciences
AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets.
Phase III CheckMate -648 trial of Opdivo shows survival benefits in oesophageal squamous cell carcinoma.- BMS
Keytruda demonstrated superior disease-free survival in KEYNOTE 564, compared with placebo as adjuvant therapy in patients with renal cell carcinoma following surgery.
Clinical value beyond price alone: biosimilars improve patient access to treatment
Long-term topical management of psoriasis: the road ahead
Over the horizon: early stage trials for NASH
Phase II trials and stem cell therapies
The next global epidemic
The latest treatments in NASH
The future of organ transplantation
Complications of stem cell transplants
Treating rejection in organ transplants
Challenges in transplant organ rejection
Biologic efficacy for complications associated with moderate-to-severe psoriasis
Moderate-to-severe psoriasis: treatment for young women
Migraine treatments: On the horizon
An independent review of current treatments for migraine
Migraine: The forgotten epidemic?
NEW: Moderate to Severe Asthma Learning Zone launches on Medthority.com
Senolytics: Can we treat age-related diseases with a single drug